Clinical trials are currently underway for the Lp-PLA2 inhibitors rilapladib and GSK2647544, which are being developed for the treatment of Alzheimer’s disease (ClinicalTrials.gov Identifier: NCT01428453 and NCT01702467). Here, PLA2G7 is linked to early-onset autosomal dominant Alzheimer disease.